A Phase II, Multi-center, Multiple-dose, Double-blind, Randomized, Crossover Study Comparing the Pharmacodynamic Effects of a Once-daily Controlled-Release Carvedilol (CRC; Egalet® Formulation) and an Immediate-Release Carvedilol (IRC) Formulation in Patients With Primary Hypertension
Phase of Trial: Phase II
Latest Information Update: 12 Sep 2016
At a glance
- Drugs Carvedilol (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Egalet
- 13 Feb 2008 Status changed from suspended to discontinued, as reported in ClinicalTrials.gov.
- 27 Aug 2007 Status changed from recruiting to suspended.
- 30 Apr 2007 New trial record.